HYDREIGHT TECHNOLOGIES INC (NURS.CA) Stock Fundamental Analysis

TSX-V:NURS • CA44877L1013

3.98 CAD
+0.28 (+7.57%)
Last: Feb 18, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to NURS. NURS was compared to 8 industry peers in the Health Care Technology industry. NURS has an average financial health and profitability rating. NURS is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • NURS had positive earnings in the past year.
  • In the past year NURS had a positive cash flow from operations.
NURS.CA Yearly Net Income VS EBIT VS OCF VS FCFNURS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

  • NURS has a Return On Assets of 2.04%. This is amongst the best in the industry. NURS outperforms 100.00% of its industry peers.
  • With an excellent Return On Equity value of 4.79%, NURS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • NURS has a better Return On Invested Capital (1.46%) than 87.50% of its industry peers.
Industry RankSector Rank
ROA 2.04%
ROE 4.79%
ROIC 1.46%
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NURS.CA Yearly ROA, ROE, ROICNURS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • NURS has a better Profit Margin (1.85%) than 87.50% of its industry peers.
  • Looking at the Operating Margin, with a value of 1.48%, NURS belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 29.16%, NURS is doing worse than 62.50% of the companies in the same industry.
  • NURS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.48%
PM (TTM) 1.85%
GM 29.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
NURS.CA Yearly Profit, Operating, Gross MarginsNURS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • NURS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for NURS has been increased compared to 1 year ago.
  • NURS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NURS.CA Yearly Shares OutstandingNURS.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
NURS.CA Yearly Total Debt VS Total AssetsNURS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M

2.2 Solvency

  • NURS has an Altman-Z score of 11.45. This indicates that NURS is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 11.45, NURS is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • NURS has a Debt/Equity ratio of 0.83. This is a neutral value indicating NURS is somewhat dependend on debt financing.
  • NURS has a Debt to Equity ratio (0.83) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF N/A
Altman-Z 11.45
ROIC/WACC0.17
WACC8.77%
NURS.CA Yearly LT Debt VS Equity VS FCFNURS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 -500K -1M -1.5M

2.3 Liquidity

  • NURS has a Current Ratio of 4.47. This indicates that NURS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of NURS (4.47) is better than 87.50% of its industry peers.
  • NURS has a Quick Ratio of 4.47. This indicates that NURS is financially healthy and has no problem in meeting its short term obligations.
  • NURS has a Quick ratio of 4.47. This is amongst the best in the industry. NURS outperforms 87.50% of its industry peers.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
NURS.CA Yearly Current Assets VS Current LiabilitesNURS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 128.24% over the past year.
  • The Revenue has grown by 59.17% in the past year. This is a very strong growth!
  • The Revenue has been growing by 137.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)128.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%426.09%
Revenue 1Y (TTM)59.17%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%132.42%

3.2 Future

  • Based on estimates for the next years, NURS will show a very strong growth in Earnings Per Share. The EPS will grow by 279.00% on average per year.
  • NURS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 115.07% yearly.
EPS Next Y488.46%
EPS Next 2Y440.3%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue Next Year130.67%
Revenue Next 2Y151.79%
Revenue Next 3Y115.07%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NURS.CA Yearly Revenue VS EstimatesNURS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
NURS.CA Yearly EPS VS EstimatesNURS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • NURS is valuated quite expensively with a Price/Earnings ratio of 398.00.
  • Based on the Price/Earnings ratio, NURS is valued cheaper than 87.50% of the companies in the same industry.
  • NURS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.27.
  • The Price/Forward Earnings ratio is 14.07, which indicates a correct valuation of NURS.
  • Based on the Price/Forward Earnings ratio, NURS is valued cheaper than 100.00% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.16. NURS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 398
Fwd PE 14.07
NURS.CA Price Earnings VS Forward Price EarningsNURS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

  • 75.00% of the companies in the same industry are more expensive than NURS, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 319.35
NURS.CA Per share dataNURS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

  • NURS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NURS's earnings are expected to grow with 279.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y440.3%
EPS Next 3Y279.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NURS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HYDREIGHT TECHNOLOGIES INC

TSX-V:NURS (2/18/2026, 7:00:00 PM)

3.98

+0.28 (+7.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-26
Earnings (Next)04-29
Inst Owners1.24%
Inst Owner ChangeN/A
Ins Owners2.03%
Ins Owner ChangeN/A
Market Cap212.41M
Revenue(TTM)24.48M
Net Income(TTM)453.30K
Analysts80
Price Target9.44 (137.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-12.44%
Min Revenue beat(2)-33.59%
Max Revenue beat(2)8.7%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.65%
PT rev (3m)8.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-66.67%
EPS NY rev (1m)14.29%
EPS NY rev (3m)-55.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-37.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-28.75%
Valuation
Industry RankSector Rank
PE 398
Fwd PE 14.07
P/S 8.68
P/FCF N/A
P/OCF 291.94
P/B 22.42
P/tB 29.63
EV/EBITDA 319.35
EPS(TTM)0.01
EY0.25%
EPS(NY)0.28
Fwd EY7.11%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.01
OCFY0.34%
SpS0.46
BVpS0.18
TBVpS0.13
PEG (NY)0.81
PEG (5Y)N/A
Graham Number0.2
Profitability
Industry RankSector Rank
ROA 2.04%
ROE 4.79%
ROCE 2.03%
ROIC 1.46%
ROICexc N/A
ROICexgc N/A
OM 1.48%
PM (TTM) 1.85%
GM 29.16%
FCFM N/A
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
F-Score5
Asset Turnover1.1
Health
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF N/A
Debt/EBITDA 12.5
Cap/Depr 535.2%
Cap/Sales 5.89%
Interest Coverage 250
Cash Conversion 115.22%
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z 11.45
F-Score5
WACC8.77%
ROIC/WACC0.17
Cap/Depr(3y)341%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%426.09%
EPS Next Y488.46%
EPS Next 2Y440.3%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue 1Y (TTM)59.17%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%132.42%
Revenue Next Year130.67%
Revenue Next 2Y151.79%
Revenue Next 3Y115.07%
Revenue Next 5YN/A
EBIT growth 1Y124.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year570.31%
EBIT Next 3Y303.71%
EBIT Next 5YN/A
FCF growth 1Y46.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y313.05%
OCF growth 3YN/A
OCF growth 5YN/A

HYDREIGHT TECHNOLOGIES INC / NURS.CA FAQ

Can you provide the ChartMill fundamental rating for HYDREIGHT TECHNOLOGIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to NURS.CA.


What is the valuation status of HYDREIGHT TECHNOLOGIES INC (NURS.CA) stock?

ChartMill assigns a valuation rating of 5 / 10 to HYDREIGHT TECHNOLOGIES INC (NURS.CA). This can be considered as Fairly Valued.


How profitable is HYDREIGHT TECHNOLOGIES INC (NURS.CA) stock?

HYDREIGHT TECHNOLOGIES INC (NURS.CA) has a profitability rating of 4 / 10.


How financially healthy is HYDREIGHT TECHNOLOGIES INC?

The financial health rating of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is 5 / 10.